Skip to main content

Table 2 Patient demographics in Bevacizumab qPCR and Control sets

From: A study of gene expression markers for predictive significance for bevacizumab benefit in patients with metastatic colon cancer: a translational research study of the Hellenic Cooperative Oncology Group (HeCOG)

Variable Set
  Control Bev qPCR P-value
Patients N 72 49  
Age Median 64.5 60.1 0.0543
  Range 41-77 32-77  
   N (%) N (%)  
Chemotherapy     
 Irinotecan-based regimen   42 (58.3) 23 (46.9) 0.1084
 Oxaliplatin-based regimen   16 (22.2) 21 (42.9)  
 Both irinotecan and oxaliplatin   5 (6.9) 1 (2.0)  
 Fluoropyrimidine only   2 (2.8) 2 (4.1)  
 Erbitux only   7 (9.7) 2 (4.1)  
Best response CR 5 (6.9) 1 (2.0) 0.5364
  PR 26 (36.1) 17 (34.7)  
  SD 16 (22.2) 14 (28.6)  
  PD 9 (12.5) 10 (20.4)  
  NE/Missing Data 16 (22.3) 7 (14.3)  
Histological grade 1-2 50 (69.4) 34 (69.4) 0.8638
  3-4 19 (26.4) 12 (24.4)  
Primary site Left 54 (75.0) 35 (71.4) 0.6619
  Right 18 (25.0) 14 (28.6)  
Gender Female 24 (33.3) 24 (49.0) 0.0842
  Male 48 (66.7) 25 (51.0)  
Stage at biopsy I-III 25 (34.8) 16 (32.6) 0.8962
  IV 46 (63.8) 31 (63.2)  
8-month progression-free rate   39 (54.2) 25 (51.0) 0.6352
Metastasectomy   6 (8.3) 7 (14.3) 0.5480